Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

Gatzemeier, U.; Heller, Adi; Foernzler, Dorothee; Moecks, Joachim; Ward, Corrine; Rosa, Francesca; Sauter, Guido; Brennscheidt, U.

doi:10.1200/jco.2005.23.16_suppl.7028

Cited by 36 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The benefit derived from the addition of erlotinib to gemcitabine cannot be predicted based on patient characteristics as assessed by the standard processes performed in advanced and metastatic pancreatic cancer. The treatment of pancreatic cancer may be influenced by the potential of certain biomarkers to predict better response to moleculartargeted therapies (as seen in non-small cell lung cancer [NSCLC] with erlotinib and another HER-1/EGFR TKI gefitinib; also in colorectal cancer with cetuximab) [43][44][45][46][47][48][49][50][51]. The advantage of individualizing therapy to patients could be possible if we could better understand which factors predict response to treatment.…”

Section: Erlotinibmentioning

confidence: 99%

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

Burris

Rocha-Lima

2008

The Oncologist

View full text Add to dashboard Cite

After completing this course, the reader will be able to:1. Evaluate the existing chemotherapeutic options for advanced pancreatic cancer.2. Interpret data from trials of HER-1/EGFR-and VEGFR-targeted agents in advanced pancreatic cancer.3. Take advantage of the potential of biomarkers in selecting optimal molecular-targeted therapies for advanced pancreatic cancer.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACT

show abstract

Section: Erlotinibmentioning

confidence: 99%

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

Burris

Rocha-Lima

2008

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Two randomized, phase III trials of erlotinib in combination with chemotherapy in first-line NSCLC failed to meet their primary end point of improved survival (19,20). However, in both trials, patients who had never smoked experienced a marked survival benefit (19,21). In a phase III, randomized trial in pancreatic cancer (PA.3), erlotinib plus gemcitabine significantly prolonged survival and progressionfree survival compared with gemcitabine alone (22), which led to approval of erlotinib in the United States for the treatment of advanced pancreatic cancer in combination with gemcitabine.…”

mentioning

confidence: 99%

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

Hanauske

Cassidy

Sastre

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Erlotinib (Tarceva) is a potent epidermal growth factor receptor (HER1) inhibitor.Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard therapy for colorectal cancer. This trial assessed the maximum tolerated dose (MTD), safety, preliminary efficacy, and pharmacokinetics of erlotinib combined with FOLFOX. Results:Thirty-two patients were enrolled (23 with colorectal cancer): no dose-limiting toxicities (DLT) were observed in cohort 1. In cohort 2, two of nine patients experienced a DLT (both diarrhea). In cohort 3, two of nine patients had a DLT (diarrhea and staphylococcal septicemia). Cohort 3 determined the MTD cohort and expanded to 17 patients in total. The most common adverse events were diarrhea, nausea, stomatitis, and rash (primarily mild/moderate). No pharmacokinetics interactions were observed. One patient (colorectal cancer) had a complete response, seven patients had a partial response, and nine had stable disease. Conclusions: The MTD was defined as follows: 150 mg/d erlotinib, 85 mg/m 2 oxaliplatin; 200 mg/m 2 leucovorin, 400 mg/m 2 bolus 5-FU, and 600 mg/m 2 infusion 5-FU. At the MTD, the combination was well tolerated and showed antitumor activity, warranting further investigation in patients with advanced colorectal cancer and other solid tumors.

show abstract

“…For example, first-line treatment with erlotinib (150 mg day À1 ) combined with standard platinum-based chemotherapy did not improve survival in the overall population of patients with advanced NSCLC; although never-smokers did experience a significant survival benefit in a post-randomisation analysis (Gatzemeier et al, 2004(Gatzemeier et al, , 2005Herbst et al, 2005). In contrast, erlotinib with gemcitabine prolonged survival somewhat in patients with previously untreated advanced pancreatic cancer compared with gemcitabine alone (Moore et al, 2005).…”

Section: Discussionmentioning

confidence: 99%

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

et al. 2008

View full text Add to dashboard Cite

The safety and maximum tolerated dose (MTD) of erlotinib with docetaxel/carboplatin were assessed in patients with ovarian cancer. Chemonaive patients received intravenous docetaxel (75 mg m À2 ) and carboplatin (area under the curve 5) on day 1 of a 3-week cycle, and oral erlotinib at 50 (cohort 1), 100 (cohort 2a) or 75 mg day À1 (cohort 2b) for up to six cycles. Dose-limiting toxicities were determined in cycle 1. Forty-five patients (median age 59 years) received treatment. Dose-limiting toxicities occurred in 1/5/5 patients (cohorts 1/2a/2b). The MTD of erlotinib in this regimen was determined to be 75 mg day À1 (cohort 2b; the erlotinib dose was escalated to 100 mg day À1 in 11 out of 19 patients from cycle 2 onwards). Neutropaenia was the predominant grade 3/4 haematological toxicity (85/100/95% respectively). Common non-haematological toxicities were diarrhoea, fatigue, nausea and rash. There were five complete and seven partial responses in 23 evaluable patients (52% response rate). Docetaxel/carboplatin had no measurable effect on erlotinib pharmacokinetics. In subsequent single-agent maintenance, erlotinib was given at 100 -150 mg day À1 , with manageable toxicity, until tumour progression. Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy.

show abstract

Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)

Cited by 36 publications

References 0 publications

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways

Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers

Contact Info

Product

Resources

About